Literature DB >> 26436329

Dasatinib-induced nephrotic syndrome.

Taichi Hirano1, Miyuki Hashimoto2, Yu Korogi2, Takahiro Tsuji1, Kei Miyanaka2, Hiroshi Yamasaki1, Hiroyuki Tsuda1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26436329     DOI: 10.3109/10428194.2015.1075020

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  5 in total

1.  Clinical features, diagnosis, and management of dasatinib-induced nephrotic syndrome.

Authors:  Yang He; Weijin Fang; Zuojun Li; Chunjiang Wang
Journal:  Invest New Drugs       Date:  2022-07-22       Impact factor: 3.651

Review 2.  Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review.

Authors:  Kenar D Jhaveri; Rimda Wanchoo; Vipulbhai Sakhiya; Daniel W Ross; Steven Fishbane
Journal:  Kidney Int Rep       Date:  2016-09-21

3.  Dasatinib-induced nephrotic syndrome in a patient with chronic myelogenous leukemia: a case report.

Authors:  Shoko Ochiai; Yuji Sato; Akihiro Minakawa; Akihiro Fukuda; Shouichi Fujimoto
Journal:  BMC Nephrol       Date:  2019-03-07       Impact factor: 2.388

4.  Dasatinib-induced nephrotic syndrome: a case of phenoconversion.

Authors:  Inga Mandac Rogulj; Vid Matišić; Borna Arsov; Luka Boban; Alen Juginović; Vilim Molnar; Dragan Primorac
Journal:  Croat Med J       Date:  2019-06-13       Impact factor: 1.351

Review 5.  Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations.

Authors:  Luca Piscitani; Vittorio Sirolli; Lorenzo Di Liberato; Manrico Morroni; Mario Bonomini
Journal:  Int J Mol Sci       Date:  2020-07-10       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.